Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.47 AUD
Change Today +0.005 / 1.09%
Volume 224.2K
As of 1:10 AM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

benitec biopharma ltd (BLT) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/7/15 - A$1.08
52 Week Low
09/30/15 - A$0.44
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BENITEC BIOPHARMA LTD (BLT)

Related News

No related news articles were found.

benitec biopharma ltd (BLT) Related Businessweek News

No Related Businessweek News Found

benitec biopharma ltd (BLT) Details

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing technology, DNA-directed RNA interference (ddRNAi) in Australia. Its in-house development programs include TT-034, which is in Phase I/IIa clinical trials for the treatment of hepatitis C; Hepbarna for the treatment of the hepatitis B virus; Tribetarna for treating drug resistant non-small cell lung cancer; and Pabparna to treat oculopharyngeal muscular dystrophy, an autosomal-dominant inherited, slow-progressing, and late-onset degenerative muscle disorder that occurs at the age of 40 or 50 years in patients, as well as a single dose treatment for wet age-related macular degeneration. The company also licenses its ddRNAi technology to other biopharmaceutical companies for various clinical applications comprising HIV/AIDS, cancer immunotherapy, retinitis pigmentosa, huntington’s diseases, and intractable neuropathic pain. Benitec Biopharma Limited was founded in 1997 and is headquartered in Sydney, Australia.

Founded in 1997

benitec biopharma ltd (BLT) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$400.0K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$230.0K
Chief Business Officer
Total Annual Compensation: A$275.0K
Founding Scientist and Head of Discovery
Total Annual Compensation: A$161.3K
Chief Clinical Officer
Total Annual Compensation: A$83.3K
Compensation as of Fiscal Year 2015.

benitec biopharma ltd (BLT) Key Developments

Benitec Initiates a Fourth Site in Hepatitis C Clinical Trial

Benitec Biopharma Limited announced it has initiated a new site for its ongoing Phase 1/2a TT-034 trial at the Methodist Health System Clinical Research Institute in Dallas, Texas. The site has commenced pre-screening hepatitis C patients and is led by principal investigator Dr. Parvez Mantry. This brings the total number of trial sites to four, with Benitec already having established sites at the Duke Clinical Research Institute, the University of California San Diego and the Texas Liver Institute. More detail on the TT-034 trial: TT-034 is a ddRNAi-based therapeutic, designed to treat and potentially cure hepatitis C (HCV) with a single administration. TT-034 targets the hepatitis C viral RNA at three separate, highly conserved sites. As such it acts as a "triple therapy" even though it is a monotherapy, and minimises the ability of the virus to mutate and escape the therapy. Once it reaches the liver cells it enters the nucleus and produces three separate short hairpin RNAs continuously for the lifetime of the cell. Thus it has the potential to not only treat the existing HCV infection but to guard against reinfection for months to years without the need to re-treat. It has been extensively tested in pre-clinical in vivo studies and no adverse effects were seen at any therapeutic dose. However, as it is regulated as a gene therapy, the trial design is to primarily ensure that treatment with TT-034 is safe, hence the gradual dose escalation.

Benitec Biopharma Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2015

Benitec Biopharma Limited reported audited consolidated earnings results for the year ended June 30, 2015. For the period, the company reported revenue of AUD 1,081,000 against AUD 598,000 a year ago. Loss before income tax benefit was AUD 11,509,000 against AUD 7,493,000 a year ago. Loss after income tax benefit for the year attributable to the owners of the company was AUD 11,509,000 or 9.96 cents per basic and diluted share compared to AUD 7,039,000 or 7.78 cents per basic and diluted share a year ago. Net cash used in operating activities was AUD 9,692,000 against AUD 9,271,000 a year ago. Payments for property, plant and equipment was AUD 505,000 against AUD 32,000 a year ago.

Benitec Biopharma Limited(NasdaqCM:BNTC) added to NASDAQ Composite Index

Benitec Biopharma Limited has been added to Nasdaq Composite Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLT:AU A$0.47 AUD +0.005

BLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dicerna Pharmaceuticals Inc $8.88 USD +0.21
Galena Biopharma Inc $1.77 USD +0.12
Marina Biotech Inc $0.33 USD +0.03
Regulus Therapeutics Inc $6.55 USD +0.05
Silence Therapeutics PLC 230.00 GBp 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.3x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BENITEC BIOPHARMA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at